Matter Bio, a biotech company dedicated to preserving genome integrity and extending healthy human lifespan secures $7million in seed funding.
With involvement from quadraScope Ventures and other investors, Lifespan Vision Ventures led the round. NIH, NCI, and NIEHS provided grants for the project.
The company plans to file an IND, begin a Phase 1/2a clinical trial in solid cancer, and carry out additional research into the information theory of ageing at a genetic level with the money.
Read also – [Funding News] NYC-based Authentic Secures $11Million in Series A Round Funding
At the vanguard of longevity biotechnology, Matter Bio tackles the difficulties of ageing by combining cutting-edge research and creative thinking. It takes a comprehensive approach to tackling the issue of genomic instability, employing multiple strategies:
Reversing: Bringing back the original genetic information and fixing incorporated mutations.
Removing: Getting rid of cells that can’t be fixed, like clonal, senescent, and malignant cells.
Together with co-founders George Church, PhD, a pioneer in genome sequencing and gene editing, Jan Vijg, PhD, a specialist in genome instability and somatic mutations, and Claudia Gravekamp, PhD, a specialist in attenuated bacterial therapeutics, the company has assembled a team of scientists and executives.
George Church, Professor of Genetics at Harvard Medical School said, “Genomic integrity is a cornerstone of longevity and healthspan extension, Matter Bio is pioneering a crucial approach in the fight against aging by focusing on the preservation of our genetic blueprint. I am excited to see the impact of their work on enhancing human health.”
Andrew Worden, Founding Partner of LifeSpan Vision Ventures said, “Our investment in Matter Bio furthers our mission of supporting the cutting-edge interventions that promote longevity and combat aging, Matter Bio’s strong team, cutting-edge genomic preservation technologies, and early-stage partnerships give the company excellent prospects to succeed with its vision.”
About Matter Bio
Maintaining genetic integrity is the primary goal of Matter Bio, a lifespan holding business. Both endogenous and external factors continuously harm their genome as they become older. On rare occasions, mistakes are overlooked and end up ingrained in the DNA as mutations, structural changes, epigenetic drift, and other kinds of data loss.
